Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Wave Biotech, PDL Biopharma, Trellis Tech, Genedata, ChemAxon

Premium
Invitrogen, Wave Biotech to Jointly Supply Media-filled Disposable Bioreactor
 
Invitrogen will team with Wave Biotech to supply media-filled disposable bioreactors, Invitrogen said this week.
 
Through the agreement, Invitrogen will supply users of Wave Biotech's Wave Bioreactor with its GIBCO cell culture media products.
 
Invitrogen's standard and custom media products will be available in Wave’s O-series Cellbags, which may be customized for specific cell culture needs, the companies said.
 
The supply partnership is expected to "substantially reduce” preparation time and the risk for contamination, the companies said.
 

 
PDL Biopharma to Use Trellis Tech for mAb Discovery
 
Trellis Bioscience this week said that PDL Biopharma will use Trellis’ CellSpot technology to discover monoclonal antibodies directed against a proprietary PDL antigen.
 
Under the terms of the agreement, Trellis will use Antibody CellSpot to screen large populations of antibody-producing cells developed by both companies using a variety of immunization strategies. PDL Biopharma will develop and commercialize any products discovered during the collaboration, and Trellis will receive an upfront fee, milestone payments, and royalties on such products.
 
Further financial details were not disclosed.
 

 
Genedata, ChemAxon Integrate Lead Discovery Software
 
Genedata has integrated its lead-discovery software with ChemAxon’s chemical visualization technology, Genedata said this week.
 
The integration will join Genedata’s Hit Profiler software with ChemAxon’s MarinView, and will be used in identifying novel drug candidates.
 
MarinView is used for visualizing and managing chemical structure information, Genedata said, adding that the integration allows the companies to “evolve their solutions independently, yet maintain interoperability.”

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.